KCPG
OMED

Kavar Capital Partners Group’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Kavar Capital Partners Group’s Portfolio OMED Stock Details OMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-18
Closed – – 582
2015
Q2 		$0 Buy
+18
New +$444 ﹤0.01% 556

Other funds holding OMED

ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Apex Capital Orinda, California $938M AUM 4.67% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Kavar Capital Partners Group's OMED Position: Q3 2015 in Review

Kavar Capital Partners Group sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q3 2015, closing a stake of 18 shares.

Kavar Capital Partners Group first reported a position in OMED in Q2 2015 and held it in 1 quarter. The position peaked at $0 in Q2 2015. 87 funds tracked by Wall St. Rank hold OMED as of Q3 2015.

  • Kavar Capital Partners Group reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q3 2015 after selling out during the quarter.
  • Kavar Capital Partners Group sold 18 OncoMed Pharmaceuticals, Inc. shares in Q3 2015.
  • Kavar Capital Partners Group first reported a position in OncoMed Pharmaceuticals, Inc. in Q2 2015 and held it in 1 quarter.
  • Kavar Capital Partners Group's OncoMed Pharmaceuticals, Inc. position peaked at $0 in Q2 2015.
  • 87 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q3 2015.

Based on Kavar Capital Partners Group's 13F filing for Q3 2015, filed 1 May 2019.